McKesson Corporation (NYSE:MCK – Get Free Report) CAO Napoleon Rutledge, Jr. sold 133 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $764.00, for a total transaction of $101,612.00. Following the transaction, the chief accounting officer directly owned 632 shares in the company, valued at approximately $482,848. This represents a 17.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
McKesson Stock Down 1.1%
NYSE MCK opened at $767.06 on Tuesday. The company has a 50-day simple moving average of $804.38 and a two-hundred day simple moving average of $848.26. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00. The firm has a market cap of $92.20 billion, a price-to-earnings ratio of 19.94, a PEG ratio of 1.28 and a beta of 0.31.
McKesson (NYSE:MCK – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $11.69 EPS for the quarter, topping the consensus estimate of $11.56 by $0.13. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The firm had revenue of $96.30 billion for the quarter, compared to the consensus estimate of $101.35 billion. During the same quarter in the previous year, the business earned $10.12 earnings per share. The company’s quarterly revenue was up 6.0% on a year-over-year basis. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Equities analysts expect that McKesson Corporation will post 44.28 earnings per share for the current fiscal year.
McKesson Dividend Announcement
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on MCK shares. Barclays raised their target price on shares of McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. UBS Group upped their price target on shares of McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Friday, May 8th. Weiss Ratings lowered shares of McKesson from a “buy (b+)” rating to a “buy (b)” rating in a report on Monday, May 18th. William Blair initiated coverage on shares of McKesson in a research report on Tuesday, April 28th. They issued an “outperform” rating on the stock. Finally, Bank of America lowered their price objective on shares of McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $968.87.
Institutional Investors Weigh In On McKesson
Hedge funds have recently made changes to their positions in the company. Parallel Advisors LLC boosted its holdings in shares of McKesson by 3.0% during the 1st quarter. Parallel Advisors LLC now owns 2,878 shares of the company’s stock valued at $2,491,000 after buying an additional 83 shares in the last quarter. First Nebraska Trust Co bought a new position in shares of McKesson in the 1st quarter worth about $723,000. Lavelle Capital LP purchased a new position in McKesson during the 1st quarter valued at about $398,000. Alpine Woods Capital Investors LLC lifted its position in McKesson by 45.8% during the 1st quarter. Alpine Woods Capital Investors LLC now owns 856 shares of the company’s stock valued at $741,000 after acquiring an additional 269 shares during the period. Finally, Allen Capital Group LLC boosted its stake in McKesson by 17.7% during the first quarter. Allen Capital Group LLC now owns 333 shares of the company’s stock worth $288,000 after acquiring an additional 50 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors.
About McKesson
McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.
The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.
Further Reading
- Five stocks we like better than McKesson
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.
